Heron Therapeutics enters supply agreement with Patheon and Thermo Fisher
Janux Therapeutics Inc. reached a new 52-week low, with its stock price falling to 22.25 USD. This recent dip underscores a challenging year for the biotechnology company, which has seen its stock value decline by 37.03% over the past 12 months. With a beta of 2.85, the stock has shown significant volatility compared to the broader market. According to InvestingPro data, the company maintains a strong balance sheet with a current ratio of 58.47, indicating robust liquidity. The drop to this new low reflects ongoing investor concerns amid broader market volatility and sector-specific challenges. As Janux Therapeutics continues to navigate these turbulent times, market participants will be closely monitoring any strategic moves or developments that could potentially reverse this downward trend. With the company’s next earnings report due on August 12 and analyst price targets ranging from $25 to $200, investors seeking deeper insights can access additional analysis and 8 more key ProTips through InvestingPro.
In other recent news, Janux Therapeutics held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on, including the election of three Class I directors. The directors elected to serve until 2028 are David Campbell, Ph.D., Ron Barrett, Ph.D., and Winston Kung. Additionally, the company ratified its independent registered public accounting firm and approved executive compensation plans. Meanwhile, Raymond (NSE:RYMD) James initiated coverage on Janux Therapeutics with an Outperform rating, setting a price target of $65.00. This decision was based on promising preliminary results for JANX007, a therapy for metastatic castration-resistant prostate cancer. In another analyst update, Leerink Partners adjusted its price target for Janux Therapeutics from $91.00 to $89.00 but maintained an Outperform rating. Leerink expressed optimism regarding Janux’s innovative cancer treatment approach and highlighted the potential of its lead product, JANX007. The company is expected to present a Phase 1 update on JANX007 later this year, which could be significant for its clinical and commercial trajectory.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.